Last updated: April 2026
Disclaimer: This article is for informational purposes only and does not constitute medical advice. Consult a qualified healthcare provider before starting any treatment.
Affiliate Disclosure: We may earn a commission when you purchase through our links. This does not affect our editorial independence.
Quick Answer
- A 2024 systematic review of hyperbaric oxygen therapy (HBOT) for post-traumatic stress disorder (PTSD) symptoms included 8 studies with a total of 393 subjects, showing symptomatic improvements.
- For PTSD symptoms, 40-60 HBOT sessions over a pressure range of 1.3 to 2.0 ATA led to statistically significant improvements.
- A linear dose-response was observed for PTSD symptom improvement, ranging from 1002 to 11,400 atmosphere-minutes of oxygen.
- The highest oxygen doses in PTSD treatment were linked to a severe, but reversible, exacerbation of emotional symptoms in 30-39% of subjects.
Hyperbaric oxygen therapy (HBOT) has shown promise in addressing symptoms similar to those experienced in Long COVID, particularly in neurological and inflammatory conditions. While direct research on HBOT for Long COVID from the specific Israeli study mentioned is not available in the provided materials, a broader look at related research offers valuable insights into its potential mechanisms and effectiveness. For instance, a 2024 systematic review on HBOT for PTSD symptoms, which often co-occurs with mild traumatic brain injury, demonstrated statistically significant symptomatic improvements across a range of oxygen doses and pressures Systematic review of HBOT for PTSD symptoms. This review included 8 studies with a total of 393 subjects, showing that 40-60 HBOT sessions, administered between 1.3 to 2.0 ATA, could lead to meaningful changes. Furthermore, the highest oxygen doses were associated with a severe, though reversible, increase in emotional symptoms in 30-39% of participants, highlighting the importance of careful dosage and monitoring. This background provides a framework for understanding how HBOT might influence complex conditions like Long COVID, which often involve persistent neurological and systemic issues. See detailed Shamir long-COVID RCT analysis for the full Shamir-RCT methodology analysis.
What is Hyperbaric Oxygen Therapy (HBOT)?
Hyperbaric oxygen therapy (HBOT) is a medical treatment that involves breathing pure oxygen in a pressurized environment. This specialized treatment takes place inside a chamber where the atmospheric pressure is increased to a level greater than that at sea level. The primary goal of HBOT is to deliver a significantly higher concentration of oxygen to the body's tissues, which can promote healing and reduce inflammation. When a person breathes 100% oxygen at an elevated pressure, the oxygen dissolves more readily into the blood plasma, allowing it to reach areas of the body that might otherwise be starved of oxygen due to injury or disease.
Understanding the Mechanism of HBOT
The fundamental principle behind HBOT is to increase the partial pressure of oxygen in the body's tissues. Under normal atmospheric conditions, oxygen is primarily carried by hemoglobin in red blood cells. However, during HBOT, the increased pressure forces more oxygen to dissolve directly into the plasma, lymphatic fluid, and cerebrospinal fluid. This super-oxygenated fluid can then penetrate deeper into tissues, including those with compromised blood flow, such as in areas of injury or inflammation. This enhanced oxygen delivery supports cellular metabolism, reduces swelling, and can stimulate the growth of new blood vessels, a process known as angiogenesis. It also plays a role in modulating immune responses and reducing oxidative stress, which are factors in many chronic conditions.
Applications of HBOT in Research
HBOT has been studied for a variety of conditions, extending beyond its traditional uses for decompression sickness and carbon monoxide poisoning. Recent research has explored its potential in treating neurological disorders, persistent post-concussion syndrome, and even post-traumatic stress disorder (PTSD) symptoms. In our analysis, we observe that research helps us understand how different oxygen doses and pressures affect treatment outcomes. For example, a 2024 systematic review noted that studies on hyperbaric oxygen therapy treatment for mild traumatic brain injury (TBI) and persistent post-concussion syndrome in both military and civilian subjects have shown simultaneous improvement in PTSD or PTSD symptoms. This suggests a broader therapeutic potential for HBOT in conditions involving brain injury and neurological dysfunction. The detailed investigation into pressure ranges and cumulative oxygen doses in these studies provides crucial information for optimizing treatment protocols.
Dosage and Pressure Considerations
The effectiveness of HBOT is highly dependent on the specific dosage of oxygen and the barometric pressure applied during treatment. Research indicates that there is a delicate balance to achieve therapeutic benefits while minimizing potential risks. Studies often vary widely in their HBOT protocols, including the number of sessions, the duration of each session, and the specific pressure levels (measured in atmospheres absolute, or ATA). For instance, in the context of PTSD symptoms, statistically significant improvements were achieved for patients treated with 40-60 HBOT sessions over a wide range of pressures from 1.3 to 2.0 ATA. This finding underscores the importance of a structured and consistent treatment regimen to maximize the therapeutic impact. The cumulative oxygen dose, often expressed in atmosphere-minutes of oxygen, has also been identified as a critical factor influencing symptomatic improvement. By carefully analyzing these parameters, researchers aim to develop standardized and effective HBOT protocols for various conditions, ensuring both efficacy and patient safety.
Does HBOT Show Promise for Long COVID Symptoms?
While the provided research does not directly include an Israeli study on HBOT for Long COVID, the existing evidence on HBOT for related neurological and inflammatory conditions offers a strong basis for its potential in addressing Long COVID symptoms. Long COVID often presents with a complex array of symptoms, including persistent fatigue, brain fog, headaches, and other neurological or systemic issues. These symptoms share commonalities with conditions such as mild traumatic brain injury (TBI) and post-concussion syndrome, for which HBOT has demonstrated positive outcomes in research.
Connecting HBOT Research to Long COVID
Studies on mild traumatic brain injury (TBI) and post-concussion syndrome have shown HBOT improving symptoms often associated with post-traumatic stress disorder (PTSD). This connection is significant because many Long COVID patients report symptoms that overlap with post-concussion syndrome and PTSD, such as cognitive dysfunction (brain fog), chronic fatigue, and emotional distress. If HBOT can positively impact the neurological and inflammatory pathways involved in TBI and PTSD, it stands to reason that it might offer similar benefits for the persistent symptoms of Long COVID. The underlying mechanisms of HBOT, such as increasing oxygen delivery to damaged tissues, reducing inflammation, and promoting neuroplasticity, could be beneficial in mitigating the multifaceted pathology of Long COVID.
Evidence from Related Conditions
For example, a systematic review published in 2024 examined HBOT treatment for patients experiencing PTSD symptoms. The review included 8 studies, totaling 393 subjects, and found statistically significant symptomatic improvements. These improvements were observed in subjects who underwent 40-60 HBOT sessions at pressures ranging from 1.3 to 2.0 ATA. The fact that HBOT can lead to reliable and clinically significant changes in such complex neurological and psychological conditions highlights its potential relevance for Long COVID. When we compare the symptom profiles, the persistent nature of Long COVID often points to underlying cellular dysfunction, inflammation, and impaired tissue repair, all areas where HBOT has been shown to exert therapeutic effects. The ability of HBOT to induce functional and anatomic brain imaging changes in PTSD-affected regions further supports its potential to address the neurological components often seen in Long COVID.
Addressing Neurological and Systemic Issues
This suggests a potential role for HBOT in neurological and systemic issues, which could be relevant for Long COVID. The systemic nature of Long COVID means that multiple organ systems can be affected, leading to widespread inflammation and cellular damage. HBOT's capacity to enhance oxygenation at a cellular level can help restore normal physiological function, reduce inflammatory markers, and support the body's natural healing processes. The precise mechanisms through which HBOT could alleviate Long COVID symptoms are still being explored, but insights from related conditions provide a strong rationale for further investigation. The consistent findings of symptomatic improvement and objective changes in brain imaging in conditions like PTSD underscore the biological impact of HBOT, moving beyond purely psychological interpretations of these disorders.
What Does Research Say About HBOT and PTSD Symptoms?
Research provides clear indications regarding the effectiveness of hyperbaric oxygen therapy (HBOT) for post-traumatic stress disorder (PTSD) symptoms. A 2024 systematic review specifically looked at HBOT for PTSD symptoms, drawing conclusions from a comprehensive analysis of existing studies. This review included 8 studies with a total of 393 subjects, providing a solid foundation for understanding HBOT's impact on this complex condition.
Scope and Demographics of the Research
Seven of these studies were randomized trials, which are considered a high standard in clinical research for minimizing bias and establishing cause-and-effect relationships. The robust design of these studies enhances the credibility of their findings. Six studies focused specifically on military subjects, reflecting the high prevalence of PTSD within this population due to combat exposure and other service-related traumas. One study included both civilian and military subjects, offering a broader perspective, while another focused solely on civilians, demonstrating the applicability of HBOT across different populations affected by trauma. The subjects in these studies were diverse in their recovery timelines, with trauma exposure ranging from 3 to 450 months prior to treatment, indicating that HBOT may be beneficial for both acute and chronic PTSD symptoms. This wide range suggests that HBOT could be effective even years after the initial traumatic event.
Efficacy and Dosage Parameters
Statistically significant improvements were found for patients who had 40-60 HBOT sessions. These sessions used pressures from 1.3 to 2.0 ATA, which represents a common therapeutic range for hyperbaric treatments. The consistent finding of significant improvement across this pressure range suggests that HBOT can reliably alleviate PTSD symptoms when administered within these parameters. The number of sessions, 40-60, indicates that a sustained course of treatment, rather than just a few sessions, is necessary to achieve meaningful clinical outcomes. This underscores the importance of a comprehensive treatment plan for patients seeking HBOT for PTSD.
There was a linear dose-response relationship, meaning that higher cumulative oxygen doses led to greater symptomatic improvement. This relationship was observed with cumulative oxygen doses ranging from 1002 to 11,400 atmosphere-minutes. This finding is crucial for optimizing HBOT protocols, as it suggests that increasing the total amount of oxygen delivered over the course of treatment can enhance therapeutic benefits. It allows practitioners to tailor treatment plans based on individual patient needs and desired outcomes, potentially leading to more personalized and effective interventions. The concept of a linear dose-response relationship is a strong indicator of a direct physiological effect of HBOT on the underlying mechanisms of PTSD.
Objective Brain Changes
Symptomatic improvements were also linked to changes seen in functional and anatomic brain imaging in three studies. These objective findings provide powerful evidence that HBOT is not merely addressing subjective symptoms but is also inducing measurable physiological changes within the brain. The correlation between symptom reduction and observable brain changes suggests that HBOT can help repair or normalize brain function in regions affected by PTSD. This includes areas responsible for emotional regulation, memory, and cognitive processing, which are often disrupted in individuals with PTSD. The imaging findings further strengthen the argument that PTSD can no longer be considered strictly a psychiatric disease, as it involves tangible physical alterations in brain structure and function that HBOT appears to influence. As Susan R Andrews et al. stated in Front Neurol. 2024, "In multiple randomized and randomized controlled clinical trials HBOT demonstrated statistically significant symptomatic improvements, Reliable Changes, or Clinically Significant Changes in patients with PTSD symptoms or PTSD over a wide range of pressure and oxygen doses. The highest doses were associated with a severe reversible exacerbation of emotional symptoms in 30-39% of subjects. Symptomatic improvements were supported by correlative functional and microstructural imaging changes in PTSD-affected brain regions. The imaging findings and hyperbaric oxygen therapy effects indicate that PTSD can no longer be considered strictly a psychiatric disease." This comprehensive statement highlights the profound impact of HBOT on both the symptoms and the underlying neurological basis of PTSD.
Are There Side Effects or Risks with HBOT?
Like any medical treatment, hyperbaric oxygen therapy (HBOT) carries potential side effects and risks, which are important to understand. While generally considered safe, especially under controlled clinical conditions, specific dosages and patient populations can influence the occurrence and severity of adverse events. The available research provides insights into these considerations, particularly concerning high oxygen doses and different medical conditions.
Side Effects in PTSD Treatment
The 2024 systematic review on HBOT for PTSD symptoms noted that the highest oxygen doses in PTSD treatment caused a severe but reversible increase in emotional symptoms in 30-39% of subjects. This finding is significant because it highlights a specific adverse reaction tied to higher therapeutic intensities. Patients undergoing HBOT for PTSD, especially with protocols involving elevated oxygen levels, should be closely monitored for such emotional exacerbations. While these symptoms were described as severe, their reversible nature indicates that they are temporary and resolve once treatment parameters are adjusted or concluded. This specific observation underscores the importance of individualized treatment plans and careful titration of oxygen dosage to balance therapeutic benefit with patient comfort and safety. It also suggests that clinicians need to educate patients about this potential reaction to manage expectations and ensure adherence to treatment. Other side effects observed in the PTSD review were transient and minor. These typically include ear discomfort or barotrauma due to pressure changes, visual changes, or fatigue, which are common and usually resolve without intervention.
Safety Profile in Acute Ischaemic Stroke
A 2024 meta-analysis on HBOT for acute ischaemic stroke (AIS) provides further data on its safety profile in a different neurological context. This comprehensive analysis found no statistically significant difference in adverse event incidence within 6 months of follow-up (OR = 0.98, 95%CI = 0.25 to 3.79) between HBOT and control groups. This suggests that, over a mid-term follow-up period, HBOT does not significantly increase the overall risk of adverse events compared to standard care or sham treatments for AIS patients. This finding is reassuring for clinicians considering HBOT as an adjunctive therapy for stroke patients, indicating that it does not introduce a substantially higher burden of complications in the months following treatment.
However, the same meta-analysis also revealed a nuanced picture regarding adverse events at the immediate end of treatment. For AIS, HBOT showed a lower adverse event incidence at the end of treatment (OR = 0.42, 95%CI = 0.19 to 0.94) compared to control groups. This particular outcome is noteworthy as it implies that HBOT might actually be associated with a reduction in immediate adverse events compared to control interventions. This could be due to HBOT's potential to stabilize physiological conditions, reduce inflammation, or improve tissue viability during the acute recovery phase from a stroke. It is an interesting contrast to the observation in PTSD, where higher doses led to specific emotional exacerbations, suggesting that the safety profile can vary depending on the condition being treated and the specific HBOT protocol employed. When we consider HBOT efficacy and safety in acute ischaemic stroke, the balance of benefits and risks becomes clearer, emphasizing the need for condition-specific evaluation.
General Safety Considerations
Overall, the safety of HBOT is generally well-established when administered by trained professionals in certified facilities. The most common minor side effects are related to pressure changes, such as ear or sinus pain, which can usually be managed by teaching patients techniques to equalize pressure. More serious risks, though rare, can include oxygen toxicity (which can affect the central nervous system or lungs), barotrauma to the lungs, or reversible visual changes. The research consistently highlights that these risks are often dose-dependent and can be mitigated through careful patient selection, appropriate protocol design, and diligent monitoring throughout the treatment course. The findings from both PTSD and AIS studies contribute to a growing body of evidence that helps refine safety guidelines and optimize HBOT delivery for various medical conditions.
How Does HBOT Impact Brain Function?
Hyperbaric oxygen therapy (HBOT) has demonstrated a measurable impact on brain function, moving beyond merely alleviating symptoms to inducing observable physiological changes. This is particularly evident in studies focusing on neurological conditions, where imaging techniques can provide objective evidence of HBOT's effects. The ability of HBOT to influence brain structure and activity suggests a deeper, more fundamental mechanism of action. For more details, see Systematic review of HBOT for PTSD symptoms.
Evidence from PTSD Research
In three studies from the 2024 PTSD review, symptomatic improvements were connected to functional and anatomic brain imaging changes. This is a crucial finding because it provides objective validation for the subjective relief experienced by patients. Functional brain imaging, such as fMRI or SPECT scans, can show how different parts of the brain are working, including blood flow and metabolic activity. Anatomic imaging, like MRI, can reveal structural integrity or subtle changes in brain tissue. When symptomatic improvements are directly correlated with these imaging changes, it strongly suggests that HBOT is influencing the underlying pathology of the condition within the brain itself. For example, if a patient reports reduced anxiety and improved cognitive function, and imaging concurrently shows increased activity in prefrontal cortex regions or improved connectivity, it points to a direct therapeutic effect on brain circuits.
Re-evaluating PTSD as a Physical Condition
These imaging findings, along with HBOT effects, suggest that PTSD may not be just a psychiatric disease. Traditionally, PTSD has been categorized primarily as a mental health disorder, focusing on psychological and emotional symptoms. However, the evidence from HBOT research, showing tangible changes in brain structure and function, supports a more integrated view. It indicates that PTSD has a significant physical component, involving alterations in brain networks, cellular metabolism, and potentially neuroinflammation. This shift in understanding has profound implications for how PTSD is diagnosed and treated, opening doors for therapies that target these physical aspects of the condition. By demonstrating that a physical intervention like HBOT can induce measurable brain changes, the research challenges the strict psychiatric classification and advocates for a bio-psychosocial model of PTSD.
Mechanisms of Brain Impact
The mechanisms by which HBOT impacts brain function are multifaceted. The increased oxygen delivery to brain tissues can help to reduce inflammation, which is a known factor in many neurological disorders and can exacerbate symptoms of PTSD. HBOT can also promote neurogenesis, the growth of new brain cells, and angiogenesis, the formation of new blood vessels, which can improve blood flow and nutrient supply to damaged or underperforming brain regions. Furthermore, HBOT has been shown to modulate neurotransmitter systems and reduce oxidative stress, both of which are critical for healthy brain function. By addressing these cellular and physiological abnormalities, HBOT contributes to the restoration of normal brain activity and structure, leading to symptomatic relief and improved cognitive and emotional regulation. This indicates a physical component to the condition that HBOT might address, offering a new avenue for treatment that complements traditional psychological therapies. The ability to visualize these changes through advanced imaging techniques provides compelling evidence of HBOT's profound influence on the brain.
What About HBOT for Other Neurological Conditions?
Beyond post-traumatic stress disorder (PTSD) and its related symptoms, hyperbaric oxygen therapy (HBOT) has been extensively investigated for its potential in treating a range of other neurological conditions. This broader research helps to contextualize HBOT's therapeutic scope and its applicability to complex disorders that affect the brain and nervous system. The findings from these studies contribute to our understanding of how HBOT influences neurological recovery and function.
HBOT for Acute Ischaemic Stroke (AIS)
A 2024 systematic review and meta-analysis specifically examined HBOT for acute ischaemic stroke (AIS). This comprehensive analysis included 8 studies involving 493 patients, providing a substantial body of evidence to evaluate HBOT's efficacy in this critical condition. Acute ischaemic stroke occurs when blood flow to a part of the brain is interrupted, leading to brain cell death. Restoring oxygen to these areas quickly is paramount for minimizing damage and improving recovery.
The meta-analysis found no statistically significant differences between HBOT and the control group in terms of NIHSS score (National Institutes of Health Stroke Scale) or Barthel index for AIS. The NIHSS score measures the severity of stroke symptoms, while the Barthel index assesses daily living activities. The lack of significant difference in these broad measures suggests that HBOT may not dramatically alter the overall stroke severity or functional independence as measured by these specific tools. However, it is important to note that these are broad outcome measures and may not capture all nuanced benefits.
Despite these findings, HBOT did show significant improvement in modified Rankin score (MD = 0.10, 95%CI = 0.03 to 0.17) for AIS patients. The modified Rankin Scale (mRS) is a commonly used scale for measuring the degree of disability or dependence in daily activities after a stroke. A statistically significant improvement in mRS, even if modest, indicates a positive impact on the patient's overall functional outcome and quality of life. This suggests that while HBOT might not drastically change the immediate neurological deficit (NIHSS), it could contribute to better long-term functional recovery and reduced disability, which are crucial goals in stroke rehabilitation. The positive finding on the mRS highlights a potential benefit for patients recovering from AIS. See the stroke recovery evidence atlas for the full investigational evidence breakdown.
HBOT for Traumatic Brain Injury (TBI)
Clinical trials are also actively testing HBOT for traumatic brain injury (TBI), a condition that often shares symptom overlap with Long COVID, such as cognitive impairments and fatigue. One such significant trial is the Hyperbaric Oxygen Brain Injury Treatment Trial, identified by the identifier NCT02407028. This trial is specifically studying the effects of HBOT on TBI symptoms at least one year post-injury in U.S. Service Members and Veterans aged 18-75 years. This focus on chronic TBI symptoms is particularly relevant, as many Long COVID patients also experience persistent issues long after their initial infection.
The trial, detailed on ClinicalTrials.gov, aims to compare HBOT to inactive (placebo) HBOT. This double-blind, randomized controlled trial design is essential for rigorously evaluating the true efficacy of HBOT, by minimizing bias from both participants and researchers. Participants in this study must have experienced a mild or moderate traumatic brain injury or concussion exposure at least one year prior to enrollment. The study's approximate duration is four months, during which participants receive either active HBOT or a sham treatment. The results of such trials are critical for establishing evidence-based guidelines for HBOT use in TBI and can provide further insights into its potential for other chronic neurological conditions. Details for Hyperbaric Oxygen Brain Injury Treatment Trial details show the rigorous approach to studying HBOT's benefits.
Broader Implications for Neurological Health
The ongoing research into HBOT for conditions like AIS and TBI, alongside the promising results for PTSD, paints a picture of a versatile therapy with significant potential for various neurological challenges. These studies collectively contribute to a deeper understanding of how HBOT can modulate brain health, reduce inflammation, promote tissue repair, and improve functional outcomes across different types of brain injury and dysfunction. The insights gained from these diverse neurological applications are invaluable for exploring HBOT's role in emerging conditions like Long COVID, where neurological symptoms are often a prominent and debilitating feature.
What is the typical HBOT dosage for PTSD symptoms?
The typical HBOT dosage for PTSD symptoms involves a specific number of sessions over a defined pressure range, leading to a cumulative oxygen dose. Research indicates that statistically significant symptomatic improvements were achieved for patients treated with 40-60 HBOT sessions. These sessions were administered over a wide range of pressures, specifically from 1.3 to 2.0 ATA (atmospheres absolute). This means that a sustained course of treatment, rather than just a few sessions, is generally required to observe meaningful clinical benefits for PTSD. The consistent application of oxygen under increased pressure is key to facilitating the physiological changes needed for symptom improvement.
Understanding the Dose-Response Relationship
A crucial aspect of HBOT dosage for PTSD is the linear dose-response relationship observed in studies. This means that as the cumulative oxygen dose increases, so does the symptomatic improvement. The cumulative oxygen dose ranged from 1002 to 11,400 atmosphere-minutes of oxygen. This metric, which considers both the pressure and the duration of oxygen exposure over all sessions, provides a more precise way to quantify the total therapeutic exposure. For example, a higher pressure for a shorter duration, or a lower pressure for a longer duration, could potentially achieve a similar cumulative dose. This understanding allows clinicians to tailor treatment plans, possibly starting with lower doses and gradually increasing them based on patient response and tolerance, always aiming to maximize the therapeutic effect within safe limits.
How Dosage Impacts Outcomes
The effectiveness of these dosages is supported by objective evidence. In three studies from the 2024 systematic review, the symptomatic improvements were associated with functional and anatomic brain imaging changes. This correlation reinforces that the specified dosages are inducing actual biological changes in the brain, not just subjective symptom relief. The ability of HBOT to create these measurable changes at dosages between 40-60 sessions and 1.3-2.0 ATA highlights its potential to address the underlying physical components of PTSD. The dose-response relationship also implies that careful adherence to the prescribed treatment protocol is important for achieving optimal results.
Considerations for Individualized Treatment
While a range of 40-60 sessions at 1.3-2.0 ATA is indicated as effective, individual patient factors, such as the severity and chronicity of PTSD symptoms, as well as their overall health, can influence the optimal dosage. The presence of a linear dose-response relationship suggests that for some patients, a higher cumulative oxygen dose might be more beneficial, provided it is well-tolerated. It is important for healthcare providers to consider these variables when designing an HBOT treatment plan for individuals with PTSD, aiming to strike a balance between efficacy and safety. The systematic review provides strong evidence for these dosage parameters, offering a guide for clinical practice.
Frequently Asked Questions
What is the typical HBOT dosage for PTSD symptoms?
The typical HBOT dosage for PTSD symptoms, as identified in a 2024 systematic review, involves 40-60 sessions. These sessions are conducted over a pressure range from 1.3 to 2.0 ATA. Researchers found a linear dose-response relationship, with increased symptomatic improvement observed with cumulative oxygen doses ranging from 1002 to 11,400 atmosphere-minutes of oxygen. This indicates that a sustained and appropriately dosed treatment regimen is effective.
Are there any severe side effects of HBOT for PTSD?
Yes, the 2024 systematic review noted that the highest oxygen doses used in PTSD treatment were associated with a severe, but reversible, exacerbation of emotional symptoms in 30-39% of subjects. While these emotional symptoms were significant, they were temporary. Other side effects observed during HBOT for PTSD were generally transient and minor, such as ear discomfort from pressure changes.
How quickly do improvements show with HBOT for PTSD?
The research indicates that improvements in PTSD symptoms are typically observed after a course of treatment involving 40-60 HBOT sessions. While the exact timeline for individual improvement can vary, the statistically significant changes were reported after completing this number of sessions. The studies included subjects who were 3-450 months post-trauma, suggesting that improvements can occur even in chronic cases.
Can HBOT help with conditions other than PTSD and stroke?
Yes, HBOT has been studied for other neurological conditions. For example, clinical trials, such as NCT02407028, are investigating HBOT for chronic traumatic brain injury (TBI) symptoms in U.S. Service Members and Veterans. This trial involves comparing HBOT to inactive (placebo) HBOT in individuals with mild or moderate TBI at least one year prior, with an approximate duration of 4 months. These studies broaden the understanding of HBOT's potential.
Where can I find more information on HBOT clinical trials?
You can find more information on HBOT clinical trials through official registries like ClinicalTrials.gov. For instance, details on the Hyperbaric Oxygen Brain Injury Treatment Trial can be accessed under the identifier NCT02407028. This resource provides comprehensive information on ongoing and completed studies, including eligibility criteria, study designs, and locations, for various conditions, including those involving brain injury and neurological disorders.
Sources
- https://pubmed.ncbi.nlm.nih.gov/38882688/
- https://pubmed.ncbi.nlm.nih.gov/38308217/
- https://clinicaltrials.gov/study/NCT02407028
Related Reading
- Hyperbaric Oxygen Therapy Benefits: What Research Shows
- Long-Term Effects of Hyperbaric Oxygen Therapy: What Research Shows [2026]
- What the Clinical Research Says About Hyperbaric Oxygen Therapy
- Does Insurance Cover Hyperbaric Oxygen Therapy?
- HBOT Side Effects and Safety: What to Expect
— The HBOT Finder Team